Acadia Pharmaceuticals (ACAD) Total Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $357.2 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 2.71% year-over-year to $357.2 million; the TTM figure through Mar 2026 stood at $357.2 million (down 2.71% YoY), while the FY2025 annual figure was $336.8 million, down 25.97% from the prior year.
• Total Liabilities was $357.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $336.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $455.0 million in Q4 2024 to a low of $176.8 million in Q3 2022.
• Historically, Total Liabilities has averaged $315.2 million across 5 years, with a median of $336.8 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 69.27% in 2023, then slipped 25.97% in 2025.
• A 5-year view of Total Liabilities shows it stood at $187.4 million in 2022, then soared by 69.27% to $317.2 million in 2023, then soared by 43.43% to $455.0 million in 2024, then fell by 25.97% to $336.8 million in 2025, then grew by 6.04% to $357.2 million in 2026.
• The last three Total Liabilities figures came in at $357.2 million (Q1 2026), $336.8 million (Q4 2025), and $413.5 million (Q3 2025), per Business Quant data.